New hope for advanced breast cancer: experimental drug HLD-0117 enters human testing

NCT ID NCT07524855

Recruiting now Disease control Sponsor: Halda Therapeutics OpCo, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the cancer's growth. Participants must be postmenopausal and have already tried hormone therapy and a CDK4/6 inhibitor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Locations

Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34231, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Yale- New Haven Hospital- Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.